Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir

Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir

Currently, interferon alpha and nucleos(t)ide analogues (NAs) are clinically available to treat hepatitis B virus (HBV) infection. Several NAs, including lamivudine (LMV), adefovir (ADV), entecavir (ETV) and tenofovir (TDF or TAF) have been approved and administered to chronic hepatitis B (CHB) pati...

Full description

Bibliographic Details
Main Authors:	Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Jong Chul Kim, Soree Park, Nayeon Kim, Byengjune Jae, Kyun-Hwan Kim
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Biomedicines
Subjects:	hepatitis B virus besifovir reverse transcription nucleos(t)ide analogue drug resistance
Online Access:	https://www.mdpi.com/2227-9059/10/7/1637

Similar Items

Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient
by: Jong Chul Kim, et al.
Published: (2022-01-01)

Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes
by: Ah Ram Lee, et al.
Published: (2021-02-01)

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
by: Do Seon Song, et al.
Published: (2021-04-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Lamivudine: fading into the mists of time
by: Jonggi Choi, et al.
Published: (2017-12-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma
by: Moon Haeng Hur, et al.
Published: (2021-11-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
by: Faydra I. Lieveld, et al.
Published: (2013-05-01)

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study
by: Prince Kofi Parbie, et al.
Published: (2022-08-01)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
by: Xizhan Xu, et al.
Published: (2017-07-01)

Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies
by: Yi-Tse Su, et al.
Published: (2022-08-01)

Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
by: Elisabetta Degasperi, et al.
Published: (2022-10-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine
by: Gian Paolo Caviglia, et al.
Published: (2017-12-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)

Post-liver transplant HBV infection (Review)
by: A. D. Nikogosova, et al.
Published: (2022-07-01)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
by: Peipei Wang, et al.
Published: (2023-01-01)

Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma
by: Soo Ryang Kim, et al.
Published: (2023-10-01)

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy
by: Chih-Lang Lin, et al.
Published: (2023-06-01)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
by: Bei Jiang, et al.
Published: (2022-12-01)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
by: Jianming Yang, et al.
Published: (2023-01-01)

HBV and HCV Therapy
by: Massimo Colombo, et al.
Published: (2009-10-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy
by: Chi-Jung Wu, et al.
Published: (2021-08-01)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
by: Li Liu
Published: (2020-02-01)

The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges
by: Feilin Ge, et al.
Published: (2023-12-01)

Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
by: Wei Teng, et al.
Published: (2021-04-01)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
by: Margarita Papatheodoridi, et al.
Published: (2020-02-01)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
by: Lina Wu, et al.
Published: (2021-02-01)

Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
by: Piero Colombatto, et al.
Published: (2022-03-01)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01)

<i>De novo</i> hepatitis B virus infection after liver transplantation
by: A. D. Nikogosova, et al.
Published: (2022-09-01)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
by: I-Chin Wu, et al.
Published: (2021-05-01)